Yes.
In 2018, the European Medicines Agency (EMA) decided to standardize the contraindications related to pregnancy for medications containing a retinoid, whether they are administered orally or topically.
Before this update, only oral forms of retinoids, such as isotretinoin, better known by the drug name Roaccutane, were formally contraindicated due to their proven teratogenic effects that can lead to severe congenital malformations. However, following a reevaluation of the benefit/risk ratio regarding retinoids as a whole, the EMA has extended this contraindication to topical retinoids. Indeed, these molecules play a role in embryogenesis and reproduction.
From a mechanistic perspective, the teratogenic effects of retinoids are caused by changes in cell migration and differentiation. More specifically, isotretinoin disrupts the movement of neural crest cells, a cell population crucial for the development of the nervous system, which can lead to their cell death. This disruption explains the occurrence of malformations in craniofacial, cardiac, and thymic structures characteristic of retinoids. Additionally, retinoids affect brain development, particularly in the rhombomere region, involved in the formation of certain parts of the central nervous system. This can result in severe abnormalities, such as cerebellar hypoplasia, meaning insufficient development of the cerebellum, or a malformation of the spinal cord. These effects can harm brain functions and affect intellectual and motor development. Although no study has been specifically conducted on retinol, the same precautionary principle applies to this derivative of vitamin A: this active ingredient should not be used during pregnancy.
Note : The same applies during breastfeeding. Retinoids should not be used during this period as there is a significant risk of transmission to the child.